keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/28707319/tenofovir-disoproxil-fumarate-significantly-decreases-serum-lipoprotein-levels-compared-with-entecavir-nucleos-t-ide-analogue-therapy-in-chronic-hepatitis-b-carriers
#1
A A Shaheen, M AlMattooq, S Yazdanfar, K W Burak, M G Swain, S E Congly, M A Borman, S S Lee, R P Myers, C S Coffin
BACKGROUND: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first-line treatments for chronic hepatitis B (CHB). Studies suggest lipid lowering effect of TDF in human immunodeficiency virus positive (HIV+) individuals, but the effect on lipids and cardiovascular disease (CVD) risk in CHB is unknown. AIM: To compare TDF vs ETV effects on lipid levels in CHB. METHODS: In this retrospective cohort study, data on serum lipids and CVD risk factors at baseline and ~1 year on TDF or ETV were collected from CHB carriers...
July 13, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28696237/persistent-loss-of-hbv-markers-in-serum-without-cellular-immunity-by-combination-of-peg-ifn-plus-etv-therapy-in-humanized-mice
#2
Takuro Uchida, Michio Imamura, C Nelson Hayes, Nobuhiko Hiraga, Hiromi Kan, Masataka Tsuge, Hiromi Abe-Chayama, Yizhou Zhang, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama
Nucleot(s)ide analogues and peg-interferon (PEG-IFN) treatment are the only approved therapies for chronic hepatitis B virus (HBV) infection. However, complete eradication of the virus, as indicated by persistent loss of hepatitis B surface antigen (HBsAg), is rare among treated patients. This is due to long-term persistence of the HBV genome in infected hepatocytes in the form of covalently closed circular DNA (cccDNA). In this study, we investigated whether administration of a large dose of a nucleoside analogue in combination with PEG-IFN can achieve long term loss of HBsAg in human hepatocyte chimeric mice...
July 10, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28671553/the-ultra-short-virological-dynamics-in-response-to-entecavir-or-lamivudine-during-chronic-hepatitis-b-with-spontaneous-severe-acute-exacerbation
#3
Teng-Yu Lee, Chi-Yi Chen, Hsueh-Chou Lia, Yu-Chung Hsu, Sheng-Shun Yang
BACKGROUND: Nucleos(t)ide analogue (NA) therapy could be life-saving in chronic hepatitis B (CHB) with spontaneous severe acute exacerbation (SAE). We aimed to investigate the ultra-short virological responses to NA. METHODS: We conducted a randomized controlled trial in which CHB patients with spontaneous SAE were randomized to receive lamivudine (LVD) or entecavir (ETV) between July 2012 and April 2016 (ClinicalTrials.gov: NCT01627223). The serum hepatitis B virus (HBV) viral loads on day 1 (baseline), 3, 5, 8, 15, 22, 29, 85, and 180 after initiating NA therapy were checked and analyzed...
July 3, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28669175/efficacy-of-tenofovir-based-rescue-therapy-for-chronic-hepatitis-b-patients-with-resistance-to-lamivudine-and-entecavir
#4
Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin
Background/Aims: Tenofovir disoproxil fumarate (TDF) monotherapy for 48 weeks provided a virological response comparable to that of TDF and entecavir (ETV) combination therapy in patients infected with ETV-resistant hepatitis B virus (HBV). Little long-term data in routine clinical practice are available regarding the optimal treatment of patients with ETV-resistant HBV. Methods: We investigated the long-term antiviral efficacy of combination therapy of TDF+lamivudine (LAM) or TDF+ETV compared to that of TDF monotherapy in 73 patients with resistance to both LAM and ETV...
June 30, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28651305/effects-of-entecavir-and-tenofovir-on-renal-function-in-patients-with-hepatitis-b-virus-related-compensated-and-decompensated-cirrhosis
#5
Jihye Park, Kyu Sik Jung, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
Background/Aims: The renal effects of nucleos(t)ide analogs in patients with chronic hepatitis B are controversial. We aimed to compare the impact of entecavir (ETV) and tenofovir (TDF) on renal function in patients with hepatitis B virus (HBV)-related cirrhosis. Methods: We performed a retrospective cohort study of 235 consecutive treatment-naïve patients with HBV-related cirrhosis who were treated with ETV or TDF between December 2012 and November 2013 at Severance Hospital, Seoul, Korea...
June 27, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28627473/glycyrrhetic-acid-but-not-glycyrrhizic-acid-strengthened-entecavir-activity-by-promoting-its-subcellular-distribution-in-the-liver-via-efflux-inhibition
#6
Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
Entecavir (ETV) is a superior nucleoside analogue used to treat hepatitis B virus (HBV) infection. Although its advantages over other agents include low viral resistance and the elicitation of a sharp decrease in HBV DNA, adverse effects such as hepatic steatosis, hepatic damage and lactic acidosis have also been reported. Glycyrrhizin has long been used as hepato-protective medicine. The clinical combination of ETV plus glycyrrhizin in China displays better therapeutic effects and lower rates of liver damage...
June 13, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28623307/both-interferon-alpha-and-lambda-can-reduce-all-intrahepatic-hdv-infection-markers-in-hbv-hdv-infected-humanized-mice
#7
Katja Giersch, Maria Homs, Tassilo Volz, Martina Helbig, Lena Allweiss, Ansgar W Lohse, Jörg Petersen, Maria Buti, Teresa Pollicino, Camille Sureau, Maura Dandri, Marc Lütgehetmann
Co-infection with hepatitis B (HBV) and D virus (HDV) is associated with the most severe course of liver disease. Interferon represents the only treatment currently approved. However, knowledge about the impact of interferons on HDV in human hepatocytes is scant. Aim was to assess the effect of pegylated interferon alpha (peg-IFNα) and lambda (peg-IFNλ), compared to the HBV-polymerase inhibitor entecavir (ETV) on all HDV infection markers using human liver chimeric mice and novel HDV strand-specific qRT-PCR and RNA in situ hybridization assays, which enable intrahepatic detection of HDV RNA species...
June 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28622419/the-risk-of-hepatocellular-carcinoma-is-decreasing-after-the-first-5-years-of-entecavir-or-tenofovir-in-caucasians-with-chronic-hepatitis-b
#8
George V Papatheodoridis, Ramazan Idilman, George N Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavelas, Onur Keskın, Nikolaos Gatselis, Bettina E Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L A Janssen, Pietro Lampertico
Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence beyond year 5 of entecavir/tenofovir therapy and tried to determine possible factors associated with late HCC occurrence. This European 10-center, cohort study included 1951 adult Caucasian CHB patients without HCC at baseline who received entecavir/tenofovir for ≥1 year. Of them, 1205 (62%) patients without HCC within the first 5 years of therapy have been followed for 5-10 (median: 6...
June 16, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28614914/ip-10-expression-in-patients-with-chronic-hbv-infection-and-its-ability-to-predict-the-decrease-in-hbsag-levels-after-treatment-with-entecavir
#9
Kai Zhao, Tao Yang, Mimi Sun, Wei Zhang, Yong An, Gang Chen, Lei Jin, Qinghua Shang, Wengang Song
Interferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV)...
June 30, 2017: Molecules and Cells
https://www.readbyqxmd.com/read/28611778/peg-interferon-lambda-treatment-induces-robust-innate-and-adaptive-immunity-in-chronic-hepatitis-b-patients
#10
Sandra Phillips, Sameer Mistry, Antonio Riva, Helen Cooksley, Tanya Hadzhiolova-Lebeau, Slava Plavova, Krum Katzarov, Marieta Simonova, Stephan Zeuzem, Clive Woffendin, Pei-Jer Chen, Cheng-Yuan Peng, Ting-Tsung Chang, Stefan Lueth, Robert De Knegt, Moon-Seok Choi, Heiner Wedemeyer, Michael Dao, Chang-Wook Kim, Heng-Chen Chu, Megan Wind-Rotolo, Roger Williams, Elizabeth Cooney, Shilpa Chokshi
IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data regarding its impact on host immune responses in vivo. We performed longitudinal and comprehensive immunosurveillance to assess the ability of pegylated (peg)-IFNλ to augment antiviral host immunity as part of a clinical trial assessing the efficacy of peg-IFNλ in chronic hepatitis B (CHB) patients. These patients were pretreated with directly acting antiviral therapy (entecavir) for 12 weeks with subsequent addition of peg-IFNλ for up to 32 weeks...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28603234/what-to-start-with-in-first-line-treatment-of-chronic-hepatitis-b-patients-an-italian-multicentre-observational-cohort-hbv-rer-study-group
#11
Gianluca Cuomo, Vanni Borghi, Tiziana Giuberti, Pietro Andreone, Marco Massari, Erica Villa, Antonello Pietrangelo, Gabriella Verucchi, Fabio Levantesi, Carlo Ferrari
Treatment options for chronic hepatitis B (CHB) are pegylated interferon (Peg-IFN) in minimal-mild liver fibrosis and nucleot(s)ide analogues (NUC) in more advanced disease. Since little is known about their use in daily clinical practice, we conducted a multicentre prospective study to investigate treatment regimens applied to naïve CHB patients in real life. HBV-RER is an observational multicentre Italian network that collect clinic and virologic data of patients with CHB. Among the 2527 CHB patients seen during the study period (2009 - 2012), 502 patients started a first line antiviral treatment...
June 1, 2017: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/28588691/chronic-hepatitis-b-patients-with-high-liver-fibrosis-levels-should-receive-antiviral-treatment
#12
Xu Li, Qinglong Jin, Hongqin Xu, Zetian Zhang, Hongjie Zhou, Dongqing Yan, Dongmei Li, Pujun Gao, Junqi Niu
The present study aimed to evaluate improvements in liver stiffness (LS) measured by transient elastography (TE) and associated factors in Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV). A total of 190 consecutive CHB patients who received entecavir therapy and two LS measurements (LSMs) were enrolled in this retrospective study (average age, 47 years; 137 males [72.1%]), including 111 patients without liver cirrhosis (group 0) and 79 patients with liver cirrhosis (group 1). Each patient received LSM twice with an interval of six months...
June 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28586757/nucleoside-analogs-treatment-delay-the-onset-of-hepatocellular-carcinoma-in-patients-with-hbv-related-cirrhosis
#13
Jingfeng Bi, Zheng Zhang, Enqiang Qin, Jun Hou, Shuiwen Liu, Zengmin Liu, Shuo Li, Zhenman Wei, Yanwei Zhong
Whether Nucleoside analogs (NA) treatment can delay the onset of HCC remains unclear. We retrospectively analyzed the clinical data of patients with HBV-related cirrhosis and HCC from 2000 to 2012. Cox proportional hazards model was used to explore the association between NA treatment and postponement of HCC development, the dependent variable was time interval from cirrhosis treatment towards the onset of HCC, and the covariates included age, sex, family history, compensation status at baseline. A total of 1155 HCC patients treated with NAs (n = 528, lamivudine, adefovir, entecavir) and non NA (n = 627) for more than 24 months before the occurrence of HCC were incorporated into the cohort...
May 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28574799/a-novel-entecavir-analogue-constructing-with-a-spiro-2-4-heptane-core-structure-in-the-aglycon-moiety-its-synthesis-and-evaluation-for-anti-hepatitis-b-virus-activity
#14
Hiroki Kumamoto, Misato Fukano, Shuhei Imoto, Satoru Kohgo, Yuki Odanaka, Masayuki Amano, Nobuyo Kuwata-Higashi, Hiroaki Mitsuya, Kazuhiro Haraguchi, Kiyoshi Fukuhara
Synthesis of a novel 2'-deoxy-guanine carbocyclic nucleoside 4 constructed with spiro[2.4]heptane core structure in the aglycon moiety was carried out. Radical-mediated 5-exo-dig mode cyclization and following cyclopropanation proceeded efficiently to furnish the spiro alcohol 10. Subsequent Mitsunobu-type glycosylation between 13 and 14, deoxygenation of the 2'-hydroxyl group of 16 and deprotection of 17 gave the title compound 4. Compound 4 demonstrated moderate anti-HBV activity (EC50 value of 0.12 ± 0...
June 2, 2017: Nucleosides, Nucleotides & Nucleic Acids
https://www.readbyqxmd.com/read/28562554/effectiveness-of-entecavir-or-telbivudine-therapy-in-patients-with-chronic-hepatitis-b-virus-infection-pre-treated-with-interferon-compared-with-de-novo-therapy-with-entecavir-and-telbivudine
#15
COMPARATIVE STUDY
Shaohang Cai, Jiawei Cao, Tao Yu, Muye Xia, Jie Peng
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B virus (HBV) infection. Treatment parameters included virological response, hepatitis B e antigen (HBeAg) seroconversion, and alanine aminotransferase (ALT) normalization...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28562104/liver-cirrhosis-stages-and-the-incidence-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients-receiving-antiviral-therapy
#16
Jae-Jun Shim, Chi Hyuck Oh, Jung Wook Kim, Chang Kyun Lee, Byung-Ho Kim
OBJECTIVES: Long-term antiviral therapy decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB), however, it cannot eliminate the risk. We investigated the incidence of HCC at different stages of liver cirrhosis (LC) and identified clinical predictors for HCC development during antiviral therapy. METHODS: The data from 356 treatment-naïve patients aged 40 to 69 years without a history of HCC who had received entecavir for ≥6 months were collected retrospectively...
May 31, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28554002/retrospective-analysis-of-hepatitis-b-virus-chronic-infection-in-247-patients-clinical-stages-response-to-treatment-and-poor-prognostic-factors
#17
Marlone Cunha-Silva, Fábio R T Marinho, Paulo F Oliveira, Tirzah M Lopes, Tiago Sevá-Pereira, Sonia L S Lorena, Jazon R S Almeida
BACKGROUND: Chronic hepatitis B is a major cause of cirrhosis, and the natural history of the disease has several clinical stages that should be thoroughly understood for the implementation of proper treatment. Nonetheless, curing the disease with antiviral treatment remains a challenge. AIMS: To describe the clinical course, response to treatment, and poor prognostic factors in 247 hepatitis B virus chronic infection patients treated in a tertiary hospital in Brazil...
May 26, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28540167/t-cell-associated-immunoregulation-and-antiviral-effect-of-oxymatrine-in-hydrodynamic-injection-hbv-mouse-model
#18
Xiuxiu Sang, Ruilin Wang, Yanzhong Han, Cong'en Zhang, Honghui Shen, Zhirui Yang, Yin Xiong, Huimin Liu, Shijing Liu, Ruisheng Li, Ruichuang Yang, Jiabo Wang, Xuejun Wang, Zhaofang Bai, Xiaohe Xiao
Although oxymatrine (OMT) has been shown to directly inhibit the replication of hepatitis B virus (HBV) in vitro, limited research has been done with this drug in vivo. In the present study, the antiviral effect of OMT was investigated in an immunocompetent mouse model of chronic HBV infection. The infection was achieved by tail vein injection of a large volume of DNA solution. OMT (2.2, 6.7 and 20 mg/kg) was administered by daily intraperitoneal injection for 6 weeks. The efficacy of OMT was evaluated by the levels of HBV DNA, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B core antigen (HBcAg)...
May 2017: Acta Pharmaceutica Sinica. B
https://www.readbyqxmd.com/read/28538268/etiological-factors-of-chronic-hepatitis-in-italy-a-2014-national-survey
#19
Tommaso Stroffolini, Evangelista Sagnelli, Piero L Almasio, Angelo Andriulli, Antonina Smedile, Mario Pirisi, Caterina Sagnelli, Maurizio Russello, Nicola Coppola, Massimo de Luca, Mariantonietta Pisaturo, Floriano Rosina, Giovanni B Gaeta
BACKGROUND: The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. AIM: The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. PATIENTS AND METHODS: Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed...
May 19, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28538267/cirrhosis-has-no-impact-on-therapeutic-responses-of-entecavir-for-chronic-hepatitis-b
#20
Pin-Chao Wang, Tao-Yang Wei, Tai-Chung Tseng, Hans Hsienhong Lin, Chia-Chi Wang
OBJECTIVE: As the efficacy of a direct antiviral agent is reduced in cirrhotic chronic hepatitis C patients, prolonged duration of treatment or addition of ribavirin is recommended to improve the rates of sustained virological response. However, the impact of cirrhosis on the efficacy of antiviral treatment for chronic hepatitis B (CHB) remained unclear. PATIENTS AND METHODS: This retrospective cohort study screened entecavir (ETV)-treated CHB patients in Taipei Tzu Chi Hospital from January 2007 till October 2014...
August 2017: European Journal of Gastroenterology & Hepatology
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"